697 related articles for article (PubMed ID: 15769695)
1. In vivo and in vitro evaluation of the heparin management test versus the activated coagulation time for monitoring anticoagulation level in aprotinin-treated patients during cardiac surgery.
Kim YS; Murkin JM; Adams SJ
Heart Surg Forum; 2004; 7(6):E599-604. PubMed ID: 15769695
[TBL] [Abstract][Full Text] [Related]
2. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
[TBL] [Abstract][Full Text] [Related]
3. Kaolin-based activated coagulation time measured by sonoclot in patients undergoing cardiopulmonary bypass.
Ganter MT; Monn A; Tavakoli R; Klaghofer R; Zollinger A; Hofer CK
J Cardiothorac Vasc Anesth; 2007 Aug; 21(4):524-8. PubMed ID: 17678778
[TBL] [Abstract][Full Text] [Related]
4. Effects of heparin, haemodilution and aprotinin on kaolin-based activated clotting time: in vitro comparison of two different point of care devices.
Dalbert S; Ganter MT; Furrer L; Klaghofer R; Zollinger A; Hofer CK
Acta Anaesthesiol Scand; 2006 Apr; 50(4):461-8. PubMed ID: 16548858
[TBL] [Abstract][Full Text] [Related]
5. The effects of MDCO-2010, a serine protease inhibitor, on activated clotting time in blood obtained from volunteers and cardiac surgical patients.
Kim H; Szlam F; Tanaka KA; van de Locht A; Ogawa S; Levy JH
Anesth Analg; 2012 Aug; 115(2):244-52. PubMed ID: 22584552
[TBL] [Abstract][Full Text] [Related]
6. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass.
Guzzetta NA; Monitz HG; Fernandez JD; Fazlollah TM; Knezevic A; Miller BE
Anesth Analg; 2010 Jul; 111(1):173-9. PubMed ID: 20519414
[TBL] [Abstract][Full Text] [Related]
7. Response of kaolin ACT to heparin: evaluation with an automated assay and higher heparin doses.
Despotis GJ; Alsoufiev AL; Spitznagel E; Goodnough LT; Lappas DG
Ann Thorac Surg; 1996 Mar; 61(3):795-9. PubMed ID: 8619695
[TBL] [Abstract][Full Text] [Related]
8. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
[TBL] [Abstract][Full Text] [Related]
9. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
Dietrich W; Spannagl M; Boehm J; Hauner K; Braun S; Schuster T; Busley R
Anesth Analg; 2008 Nov; 107(5):1469-78. PubMed ID: 18931201
[TBL] [Abstract][Full Text] [Related]
10. Activated clotting time, anticoagulation, use of heparin, and thrombin activation during extracorporeal circulation: changes under aprotinin therapy.
Feindt P; Volkmer I; Seyfert U; Huwer H; Kalweit G; Gams E
Thorac Cardiovasc Surg; 1993 Feb; 41(1):9-15. PubMed ID: 7690165
[TBL] [Abstract][Full Text] [Related]
11. In vitro anticoagulation monitoring of low-molecular-weight heparin.
Wang JQ; Shi XB; Yang JG; Hu DY
Chin Med J (Engl); 2009 May; 122(10):1199-202. PubMed ID: 19493471
[TBL] [Abstract][Full Text] [Related]
12. Effect of aprotinin on activated clotting time, whole blood and plasma heparin measurements.
Despotis GJ; Joist JH; Joiner-Maier D; Alsoufiev AL; Triantafillou AN; Goodnough LT; Santoro SA; Lappas DG
Ann Thorac Surg; 1995 Jan; 59(1):106-11. PubMed ID: 7529483
[TBL] [Abstract][Full Text] [Related]
13. Monitoring activated clotting time for combined heparin and aprotinin application: an in vitro evaluation of a new aprotinin-insensitive test using SONOCLOT.
Ganter MT; Dalbert S; Graves K; Klaghofer R; Zollinger A; Hofer CK
Anesth Analg; 2005 Aug; 101(2):308-314. PubMed ID: 16037133
[TBL] [Abstract][Full Text] [Related]
14. The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement.
Wendel HP; Heller W; Gallimore MJ; Bantel H; Müller-Beissenhirtz H; Hoffmeister HE
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):41-5. PubMed ID: 7681331
[TBL] [Abstract][Full Text] [Related]
15. In vitro effects of aprotinin on activated clotting time measured with different activators.
Wang JS; Lin CY; Hung WT; Thisted RA; Karp RB
J Thorac Cardiovasc Surg; 1992 Oct; 104(4):1135-40. PubMed ID: 1383640
[TBL] [Abstract][Full Text] [Related]
16. Aprotinin prolongs activated and nonactivated whole blood clotting time and potentiates the effect of heparin in vitro.
Despotis GJ; Filos KS; Levine V; Alsoufiev A; Spitznagel E
Anesth Analg; 1996 Jun; 82(6):1126-31. PubMed ID: 8638779
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of adequate heparinization during artificial circulation in the framework of prolonged intraoperative administration of high doses of aprotinin].
Dement'eva II; Charnaia MA; Shabalkin BV; Iavorovskiĭ AG; Piatnitskaia GKh
Anesteziol Reanimatol; 1994; (3):32-5. PubMed ID: 7521582
[TBL] [Abstract][Full Text] [Related]
18. The effect of aprotinin on the response of the activated partial thromboplastin time (APTT) to heparin.
Francis JL; Howard C
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):35-40. PubMed ID: 7681330
[TBL] [Abstract][Full Text] [Related]
19. Aprotinin does not prolong the Sonoclot aprotinin-insensitive activated clotting time.
Dong Y; Nuttall GA; Oliver WC; Agarwal S; Ereth MH
J Clin Anesth; 2007 Sep; 19(6):424-8. PubMed ID: 17967670
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
Despotis GJ; Joist JH
J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
